Key points
- Polynovo reported a 16.7% increase in group sales for FY26.
- NovoSorb MTX sales grew by 89.6% year-on-year.
- NovoSorb BTM sales increased by 12.3% year-on-year.
- The company expanded its commercial footprint with 252 new hospital accounts.
- Completed construction of a new manufacturing facility.
Full summary
Polynovo Ltd announced strong financial results for FY26, with group sales increasing by 16.7% to A$138.4 million. Key highlights include a significant 89.6% year-on-year growth in NovoSorb MTX sales, bringing total sales to A$12.6 million. The company added 252 new hospital accounts, expanding its commercial footprint. NovoSorb BTM sales grew by 12.3% to A$125.8 million. The company also completed the construction of a new manufacturing facility, positioning it for future growth. EBITDA increased by 50.4% to A$13.4 million, and the company ended the year with A$35.4 million in cash and cash equivalents.
Guidance
Polynovo Ltd expects continued growth in NovoSorb MTX sales and expansion of its commercial footprint in FY27.
Outlook
Polynovo Ltd is optimistic about its growth prospects in FY27, driven by the expansion of its NovoSorb MTX sales and the addition of new hospital accounts.